{"filing":{"accession_number":"0001193125-26-257376","cik":"0001680581","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"fulc-20260531.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/fulc-20260531.htm"},"events":[{"id":6797,"run_id":5956,"accession_number":"0001193125-26-257376","anchor_item_number":"2.05","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Fulcrum's board approved a comprehensive restructuring plan involving an 85% workforce reduction (from 57 to 9 employees) and $4.2 million in charges, triggered by the discontinuation of pociredir development for sickle cell disease. This represents a significant strategic pivot with material implications for the company's operational scale and capital preservation.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4323,"accession_number":"0001193125-26-257376","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a board-approved restructuring plan involving an 85% workforce reduction (57 to 9 employees) and $4.2 million in charges, triggered by discontinuation of pociredir development for sickle cell disease. While Item 2.05 typically covers exit/disposal costs, this event is fundamentally a material operational restructuring with significant strategic implications (program discontinuation, massive headcount reduction) that would affect investor assessment of the company's viability and capital preservation strategy. The event does not fit neatly into the more specific categories (not a restatement, going-concern disclosure, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:52.871270+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6798,"run_id":5956,"accession_number":"0001193125-26-257376","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Fulcrum initiated a comprehensive strategic review and engaged Leerink Partners LLC as financial advisor to evaluate potential strategic alternatives, including merger, acquisition, business combination, sale or licensing of assets, or other strategic transactions. No transaction has been approved or agreed upon at this time.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4324,"accession_number":"0001193125-26-257376","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Fulcrum has initiated a comprehensive strategic review and engaged Leerink Partners LLC as financial advisor to evaluate potential strategic alternatives \"including, but not limited to, a merger, acquisition, business combination, sale or licensing of assets, or other strategic transaction.\" This disclosure of an active strategic review process involving potential M\u0026A activity is material to investors assessing the company's future direction and value, even though no transaction has been approved yet.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:52.871270+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4323,"accession_number":"0001193125-26-257376","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a board-approved restructuring plan involving an 85% workforce reduction (57 to 9 employees) and $4.2 million in charges, triggered by discontinuation of pociredir development for sickle cell disease. While Item 2.05 typically covers exit/disposal costs, this event is fundamentally a material operational restructuring with significant strategic implications (program discontinuation, massive headcount reduction) that would affect investor assessment of the company's viability and capital preservation strategy. The event does not fit neatly into the more specific categories (not a restatement, going-concern disclosure, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:52.871270+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-04"},{"id":4324,"accession_number":"0001193125-26-257376","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Fulcrum has initiated a comprehensive strategic review and engaged Leerink Partners LLC as financial advisor to evaluate potential strategic alternatives \"including, but not limited to, a merger, acquisition, business combination, sale or licensing of assets, or other strategic transaction.\" This disclosure of an active strategic review process involving potential M\u0026A activity is material to investors assessing the company's future direction and value, even though no transaction has been approved yet.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:52.871270+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-04"}]}